SCHEMBL2901413

SCHEMBL2901413

O=C(O)c1cccc(-c2cccc(CN3CC(c4ccccc4)OC3=O)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.50
LTA4H P09960 1/20 0.45
GRM2 Q14416 3/20 0.44
PRSS12 P56730 1/20 0.43
KMT2A Q03164 1/20 0.43
KMO O15229 1/20 0.43
HDAC3 O15379 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
NCOR2 Q9Y618 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4A O75164 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
NR4A2 P43354 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901414 1.00 FADS1 (0.50) FADS1LTA4HGRM2PRSS12KMT2A
SCHEMBL2899155 0.92 GRM2 (0.54) FADS1LTA4HGRM2PRSS12KMO
SCHEMBL4318364 0.92 GRM2 (0.54) FADS1LTA4HGRM2PRSS12KMO
SCHEMBL2901621 0.85 GRM2 (0.53) FADS1LTA4HGRM2PRSS12
SCHEMBL5475116 0.85 GRM2 (0.53) FADS1LTA4HGRM2PRSS12
SCHEMBL2901397 0.85 GRM2 (0.53) FADS1LTA4HGRM2PRSS12
SCHEMBL2899915 0.84 GRM2 (0.54) FADS1LTA4HGRM2PRSS12
SCHEMBL2898909 0.84 GRM2 (0.54) FADS1LTA4HGRM2PRSS12
SCHEMBL2893979 0.84 GRM2 (0.54) FADS1LTA4HGRM2PRSS12
SCHEMBL2900422 0.83 CAMK2D (0.44) FADS1HDAC3HDAC2HDAC8NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US claimed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US claimed
EP-1994016-A2 5-PHENYL-3-BENZYL-OXAZOLIDIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS AstraZeneca AB (SE) 2008-11-26 EP claimed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US claimed
WO-2007078523-A2 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2007-07-12 WO claimed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 FADS1 4353/4885LTA4H 2150/4885GRM2 3/4885
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 FADS1 4353/4885LTA4H 2150/4885GRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.